SEC 13F Intelligence

Managers / Q3 2019 · view latest →

CVI Holdings, LLC

CIK 0001728194 · ONE COMMERCE CENTER, 1201 N. ORANGE STREET, SUITE 715, WILMINGTON, DE, 19801 · 6106172600

Reported Value
$131M
Q3 2019
Positions
107
includes revealed positions
Filings on Record
25
2019–present window
Filed
Nov 14, 2019
original filing

Summary

Cvi Holdings, LLC reported $131M in U.S.-listed holdings across 107 positions for Q3 2019.

Its largest position, SCOR1EUR, represents 10.7% of the portfolio.

Compared with Q2 2019, the fund opened 20 new positions and exited 1.

Portfolio Metrics

Turnover
+11.1%
vs prior filed quarter
Top-10 Concentration
+64.1%
share of reported value
Largest Position
+10.7%
Comscore
New / Exited
20 / 1
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $45MQ4 ’18Q1 ’19: $106MQ2 ’19: $172MQ3 ’19: $131MQ3 ’19Q4 ’19: $71MQ1 ’20: $28MQ2 ’20: $270MQ2 ’20Q3 ’20: $246MQ4 ’20: $536MQ1 ’21: $1.4BQ1 ’21Q2 ’21: $1.5BQ3 ’21: $1.6BQ4 ’21: $1.5BQ4 ’21Q1 ’22: $1.5BQ2 ’22: $1.4BQ3 ’22: $1.3BQ3 ’22Q4 ’22: $784MQ1 ’23: $266MQ2 ’23: $95MQ2 ’23Q3 ’23: $51MQ4 ’23: $48MQ1 ’24: $106MQ1 ’24Q2 ’24: $116Mfilingsflow.com

Portfolio Composition

By security type
Common Stock: 37.0%US DOMESTIC: 33.7%Other: 25.2%ADR: 4.1%
  • Common Stock · 37.0% · $49M
  • US DOMESTIC · 33.7% · $44M
  • Other · 25.2% · $33M
  • ADR · 4.1% · $5M

Quarter-over-Quarter Changes full breakdown →

vs Q2 2019 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
XCUREXICURE INCNEW+1.28M1.28M+$3M$3M
TURNING POINT THERAPEUTICS INEW+68.8K68.8K+$3M$3M
VUZIVUZIX CORPNEW+667.6K667.6K+$2M$2M
CRMDCORMEDIX INCNEW+229.5K229.5K+$1M$1M
TEUMPARETEUM CORPNEW+955.5K955.5K+$1M$1M
BTAIEURBIOXCEL THERAPEUTICS INCNEW+159.0K159.0K+$1M$1M
OCGNOCUGEN INCNEW+368.3K368.3K+$1M$1M
CTRIP COM INTL LTDNEW+21.3K21.3K+$624,000$624,000

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q3 2019REVEALED

44 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1ANI PHARMACEUTICALS INCREVEALEDNOTE 3.000%12/015.78%$21M18.00M
2TIMKENSTEEL CORPREVEALEDNOTE 6.000% 6/015.61%$20M20.91M
3SESEN BIO INCREVEALEDCOM13.50%$18M12.85M
4SCOR1EURCOMSCORE INCREVEALEDhistory →COM10.73%$14M2.73M
5EROS INTL PLCREVEALEDSHS NEW3.30%$4M2.88M
6MDCOUSDMEDICINES COREVEALEDhistory →COM3.14%$4M113.0K
7SRNESORRENTO THERAPEUTICS INCREVEALEDhistory →COM NEW2.85%$4M1.40M
8CALAEURCALITHERA BIOSCIENCES INCREVEALEDhistory →COM2.51%$3M843.2K
9XCUREXICURE INChistory →COM2.46%$3M1.28M
10SENSEONICS HLDGS INCREVEALEDNOTE 5.250% 2/02.32%$3M3.00M
11GNFTYGENFIT S AREVEALEDhistory →ADS2.08%$3M138.2K
12SRRKSCHOLAR ROCK HLDG CORPREVEALEDhistory →COM2.02%$3M167.4K
13TURNING POINT THERAPEUTICS ICOM1.97%$3M68.8K
14VASCULAR BIOGENICS LTDREVEALEDCOM1.75%$2M1.73M
15LAURLAUREATE EDUCATION INCREVEALEDhistory →CL A1.46%$2M121.8K
16ORTXUSDORCHARD THERAPEUTICS PLCREVEALEDhistory →ADS1.39%$2M130.7K
17VUZIVUZIX CORPhistory →COM NEW1.16%$2M667.6K
18CRMDCORMEDIX INChistory →COM1.12%$1M229.5K
19TEUMPARETEUM CORPCOM NEW0.94%$1M955.5K
20KURAKURA ONCOLOGY INCREVEALEDCOM0.91%$1M60.8K
21BTAIEURBIOXCEL THERAPEUTICS INCCOM0.85%$1M159.0K
22AIHSUSDSENMIAO TECHNOLOGY LTDREVEALEDCOM0.85%$1M398.3K
23OCGNOCUGEN INCCOM0.81%$1M368.3K
24ABTUGBXAQUABOUNTY TECHNOLOGIES INCREVEALEDCOM NEW0.81%$1M345.2K
25CYCNUSDCYCLERION THERAPEUTICS INCREVEALEDCOM0.69%$899,00078.6K
26TRANSLATE BIO INCREVEALEDCOM0.65%$852,00067.5K
27PSDVUSDEYEPOINT PHARMACEUTICALS INCREVEALEDCOM0.57%$748,000455.8K
28ELOXX PHARMACEUTICALS INCREVEALEDCOM0.57%$742,00074.4K
29MCRB1EURSERES THERAPEUTICS INCREVEALEDCOM0.55%$727,000225.8K
30CTRIP COM INTL LTDSPONSORED ADS0.48%$624,00021.3K
31ADAMIS PHARMACEUTICALS CORPCOM NEW0.47%$622,000883.4K
32RGLSUSDREGULUS THERAPEUTICS INCREVEALEDCOM NEW0.43%$568,000454.2K
33EKSO BIONICS HLDGS INCREVEALEDCOM NEW0.38%$494,000388.6K
34CTHRUSDCHARLES & COLVARD LTDREVEALEDCOM0.34%$452,000285.9K
35GOLDEN MINERALS COCOM0.33%$435,0001.78M
36RKDAEURARCADIA BIOSCIENCES INCREVEALEDCOM NEW0.32%$414,000135.0K
37IM8NINSMED INCREVEALEDCOM PAR $.010.29%$374,00014.6K
38ZYMEUSDZYMEWORKS INCREVEALEDCOM0.28%$373,00017.0K
39ORAGENICS INCREVEALEDCOM PAR0.26%$345,000703.1K
40BBGIEURBEASLEY BROADCAST GROUP INCREVEALEDCL A0.24%$316,00098.2K
41CELLECTAR BIOSCIENCES INCREVEALEDCOM PAR0.18%$231,000106.0K
42ARCTARCTURUS THERAPEUTICS HLDG ICOM0.17%$227,00022.1K
43OPRAOPERA LTDSPONSORED ADS0.16%$212,00021.1K
44ARTELO BIOSCIENCES INCREVEALEDCOM NEW0.14%$189,00041.1K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q2 2024$116M144Aug 15, 202413F-HRchanges · EDGAR ↗
Q1 2024$106M157May 7, 202413F-HRchanges · EDGAR ↗
Q4 2023$48M187Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$51M229Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$95M277Aug 11, 202313F-HRchanges · EDGAR ↗
Q1 2023$266M413May 16, 202313F-HRchanges · EDGAR ↗
Q4 2022$784M615Feb 14, 202313F-HRchanges · EDGAR ↗
Q3 2022$1.3B882Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$1.4B930Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$1.5B928May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$1.5B948Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$1.6B899Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$1.5B790Aug 11, 202113F-HRchanges · EDGAR ↗
Q1 2021$1.4B615May 17, 202113F-HRchanges · EDGAR ↗
Q4 2020$536M182Feb 16, 202113F-HRchanges · EDGAR ↗
Q3 2020$246M83Nov 16, 202013F-HRchanges · EDGAR ↗
Q2 2020$270M70Aug 14, 202013F-HRchanges · EDGAR ↗
Q1 2020$28M37May 15, 202013F-HRchanges · EDGAR ↗
Q4 2019$71M36Feb 14, 202013F-HRchanges · EDGAR ↗
Q3 2019REVEALED$131M107Nov 14, 201913F-HRchanges · EDGAR ↗
Q2 2019REVEALED$172M118Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$106M58May 15, 201913F-HRchanges · EDGAR ↗
Q4 2018$45M42Feb 14, 201913F-HRchanges · EDGAR ↗

Other Included Managers

This filing reports holdings on behalf of 2 additional managers.

  • HEIGHTS CAPITAL MANAGEMENT, INC028-13218
  • CVI Investments, Inc.028-17822

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.